The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Open accessAbstract
BACKGROUND Spasticity is a major determinant of disability and decline in quality of life in patients with motor neuron disease. Cannabinoids have been approved for symptomatic treatment of spasticity in multiple sclerosis. We investigated whether cannabinoids might also reduce spasticity in patients with motor neuron disease. METHODS We did an investigator-initiated, randomised, double-blind, placebo-controlled, phase 2 clinical trial at four tertiary motor neuron disease centres in Italy. Eligible patients were aged 18-80 years; had possible, laboratory-supported probable, probable, or definite amyotrophic lateral sclerosis as defined by revised El Escorial criteria, or primary lateral sclerosis according to Pringle's criteria; had spasticity symptoms due to motor neuron disease for at least 3 months; had spasticity scores of 1 or greater in at least two muscle groups on the Modified Ashworth Scale; and were taking an antispasticity regimen that was maintained at a stable dose for 30 days before enrolment. Participants were assigned (1:1) by an independent statistician via a computer-generated randomisation sequence to a standardised oromucosal spray (nabiximols) containing a defined combination of delta-9-tetrahydrocannabinol and cannabidiol (each 100 μL actuation contained 2·7 mg delta-9-tetrahydrocannabinol and 2·5 mg cannabidiol) or to placebo for 6 weeks. Participants self-titrated during the first 14 treatment days according to a predefined escalation scheme (maximum…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,424
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737
Miller, R. G., Jackson, C. E., Kasarskis, E. J., England, J. D., Forshew, D., Johnston, W., Kalra, S., Katz, J. S., Mitsumoto, H., Rosenfeld, J., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc01a4 · Cited by 674
Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study
Chio, A., Calvo, A., Moglia, C., Mazzini, L., Mora, G., & PARALS study group (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.235952 · Cited by 621
Self-citationRusso, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
Self-citation
Cited by
Wang, L., Hong, P. J., May, C., Rehman, Y., Oparin, Y., Hong, C. J., Hong, B. Y., AminiLari, M., Gallo, L., Kaushal, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1034 · Cited by 300
Immune Responses Regulated by Cannabidiol
Nichols, J. M., & Kaplan, B. L. F. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 291
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
“Amyotrophic lateral sclerosis To date, only one cross-over RCT with dronabinol [75] and one parallel RCT with nabiximols [40] have been carried out in patients suffering from ALS (Additional file 4: Fig.”
BackgroundDamme, P. V., Al‐Chalabi, A., Andersen, P. M., Chiò, A., Couratier, P., de Carvalho, M. A., Hardiman, O. M., Kuźma‐Kozakiewicz, M., Ludolph, A. C., McDermott, C. J., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16264 · Cited by 185
Therapeutic potential of PPARγ natural agonists in liver diseases
Wu, L., Guo, C., & Wu, J. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15028 · Cited by 116
Metadata
- Authors
- Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., Formaglio, F., Rossi, P., Clerici, M., Falzone, Y. M., Pozzi, L., Martinelli, D., Cerri, F., Lopez, I. D., Martinelli-Boneschi, F., Quattrini, A., Pieri, E., Marinou, K., Querin, G., Sansone, V., Maestri, E., Calvo, A., & Chio, A.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- University of Pavia (IT)
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 18
- Issue
- 2
- Pages
- 155-164
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2905561928
- Cited by
- 104
- References
- 41
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 22 · 2023: 14 · 2022: 16 · 2021: 17 · 2020: 12 · 2019: 7
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- GW Pharmaceuticals
- Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica
- Topics
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- nabiximols, cannabinoids, spasticity, motor neuron disease, amyotrophic lateral sclerosis, primary lateral sclerosis, oromucosal spray, delta-9-tetrahydrocannabinol, cannabidiol, Modified Ashworth Scale, drug safety and tolerability, self-titration, quality of life, disability progression, neuromodulation
- MeSH terms
- Adult, Aged, Cannabidiol, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Muscle Spasticity, Quality of Life, Dronabinol, Motor Neuron Disease, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30406-x
- The paper
- Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., Formaglio, F., Rossi, P., Clerici, M., Falzone, Y. M., Pozzi, L., Martinelli, D., Cerri, F., Lopez, I. D., Martinelli-Boneschi, F., . . . Chio, A. (2019). Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30406-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.